易明医药 (002826.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	670.3M	636.3M	651.9M	667.0M	856.7M
Cost of Revenue	115.9M	113.8M	205.3M	325.6M	480.6M
Gross Profit	554.4M	522.5M	446.6M	341.5M	376.2M
Operating Expenses
R&D Expense	14.1M	14.7M	15.5M	13.7M	13.4M
SG&A Expense	—	—	—	—	—
General & Admin Expense	94.7M	86.9M	49.4M	51.0M	47.2M
Selling & Marketing Expense	357.7M	346.6M	341.2M	247.3M	270.7M
Other Expenses	—	—	—	—	—
Total Operating Expenses	477.6M	459.5M	417.2M	322.1M	341.7M
Cost and Expenses	593.5M	573.4M	622.5M	647.7M	822.3M
Operating Income (EBIT)	104.4M	100.6M	61.5M	23.5M	55.7M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	117.6M	113.7M	60.4M	23.6M	56.7M
Income Tax Expense	23.7M	20.5M	12.9M	7.9M	10.6M
Bottom Line
Net Income	93.4M	92.6M	45.9M	15.4M	44.1M
Earnings from Cont. Ops	93.8M	93.1M	47.5M	15.7M	46.1M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	93.4M	92.6M	45.9M	15.4M	44.1M
Per Share
Basic EPS	CN¥0.51	CN¥0.50	CN¥0.25	CN¥0.08	CN¥0.23
Diluted EPS	CN¥0.51	CN¥0.50	CN¥0.25	CN¥0.08	CN¥0.23
Revenue Per Share	CN¥3.75	CN¥3.44	CN¥3.55	CN¥3.47	CN¥4.46
Shares
Basic Shares Outstanding	178.6M	185.2M	183.7M	192.3M	191.9M
Diluted Shares Outstanding	178.6M	185.2M	183.7M	192.3M	191.9M
Profitability Metrics
EBITDA	—	119.7M	83.2M	49.4M	80.2M
D&A	—	19.1M	21.7M	25.9M	24.5M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026